These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 23888874)

  • 1. The anticancer drug tirapazamine has antimicrobial activity against Escherichia coli, Staphylococcus aureus and Clostridium difficile.
    Shah Z; Mahbuba R; Turcotte B
    FEMS Microbiol Lett; 2013 Oct; 347(1):61-9. PubMed ID: 23888874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New insights into the antimicrobial action and protective therapeutic effect of tirapazamine towards Escherichia coli-infected mice.
    Wu Z; Wang Y; Li L; Zhen S; Du H; Wang Z; Xiao S; Wu J; Zhu L; Shen J; Wang Z
    Int J Antimicrob Agents; 2023 Sep; 62(3):106923. PubMed ID: 37433388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bactericidal activity and target preference of a piperazinyl-cross-linked ciprofloxacin dimer with Staphylococcus aureus and Escherichia coli.
    Zhao X; Quinn B; Kerns R; Drlica K
    J Antimicrob Chemother; 2006 Dec; 58(6):1283-6. PubMed ID: 17003060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and in vitro antibacterial activity of 7-(3-alkoxyimino-5-amino/methylaminopiperidin-1-yl)fluoroquinolone derivatives.
    Zhang Y; Li G; Liu M; You X; Feng L; Lv K; Cao J; Guo H
    Bioorg Med Chem Lett; 2011 Feb; 21(3):928-31. PubMed ID: 21232952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of fluoroquinolone-resistant Escherichia coli O25:H4-ST131 (CTX-M-15-nonproducing) strains isolated in Japan.
    Yokota S; Sato T; Okubo T; Ohkoshi Y; Okabayashi T; Kuwahara O; Tamura Y; Fujii N
    Chemotherapy; 2012; 58(1):52-9. PubMed ID: 22343392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of DS-2969b and comparator antimicrobial agents against Clostridioides (Clostridium) difficile, methicillin-resistant Staphylococcus aureus, and other anaerobic bacteria.
    Tyrrell KL; Citron DM; Merriam CV; Leoncio E; Goldstein EJC
    Anaerobe; 2018 Dec; 54():39-41. PubMed ID: 30096588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluoroquinolone resistance mechanisms in urinary tract pathogenic Escherichia coli isolated during rapidly increasing fluoroquinolone consumption in a low-use country.
    Christiansen N; Nielsen L; Jakobsen L; Stegger M; Hansen LH; Frimodt-Møller N
    Microb Drug Resist; 2011 Sep; 17(3):395-406. PubMed ID: 21668371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Large-scale analysis of genes that alter sensitivity to the anticancer drug tirapazamine in Saccharomyces cerevisiae.
    Hellauer K; Lesage G; Sdicu AM; Turcotte B
    Mol Pharmacol; 2005 Nov; 68(5):1365-75. PubMed ID: 16061773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid and sensitive detection of fluoroquinolone-resistant Escherichia coli from urine samples using a genotyping DNA microarray.
    Yu X; Susa M; Weile J; Knabbe C; Schmid RD; Bachmann TT
    Int J Med Microbiol; 2007 Oct; 297(6):417-29. PubMed ID: 17482874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dichotomous selection of high-level oxacillin resistance in Staphylococcus aureus by fluoroquinolones.
    Dalhoff A; Schubert S
    Int J Antimicrob Agents; 2010 Sep; 36(3):216-21. PubMed ID: 20630710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adaptation of human tumor cells to tirapazamine under aerobic conditions: implications of increased antioxidant enzyme activity to mechanism of aerobic cytotoxicity.
    Elwell JH; Siim BG; Evans JW; Brown JM
    Biochem Pharmacol; 1997 Jul; 54(2):249-57. PubMed ID: 9271329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prevalence of qnr genes in clinical Enterobacteriaceae non-susceptible to fluoroquinolone in Poland].
    Piekarska K; Rzeczkowska M; Zacharczuk K; Chróst A; Januszkiewicz A; Bareja E; Olak M; Gierczyński R
    Med Dosw Mikrobiol; 2012; 64(3):211-9. PubMed ID: 23285775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploration of the activity of 7-pyrrolidino-8-methoxyisothiazoloquinolones against methicillin-resistant Staphylococcus aureus (MRSA).
    Kim HY; Wiles JA; Wang Q; Pais GC; Lucien E; Hashimoto A; Nelson DM; Thanassi JA; Podos SD; Deshpande M; Pucci MJ; Bradbury BJ
    J Med Chem; 2011 May; 54(9):3268-82. PubMed ID: 21425851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bactericidal activity of fluoroquinolones against plasmid-mediated QnrA-producing Escherichia coli.
    Mammeri H; Poirel L; Nordmann P
    Clin Microbiol Infect; 2005 Dec; 11(12):1048-9. PubMed ID: 16307564
    [No Abstract]   [Full Text] [Related]  

  • 15. The continuing crisis in antibiotic resistance.
    French GL
    Int J Antimicrob Agents; 2010 Nov; 36 Suppl 3():S3-7. PubMed ID: 21129629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-level resistance to moxifloxacin and gatifloxacin associated with a novel mutation in gyrB in toxin-A-negative, toxin-B-positive Clostridium difficile.
    Drudy D; Quinn T; O'Mahony R; Kyne L; O'Gaora P; Fanning S
    J Antimicrob Chemother; 2006 Dec; 58(6):1264-7. PubMed ID: 17018563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-heterocyclic dicarboxylic acids: broad-spectrum inhibitors of metallo-β-lactamases with co-antibacterial effect against antibiotic-resistant bacteria.
    Feng L; Yang KW; Zhou LS; Xiao JM; Yang X; Zhai L; Zhang YL; Crowder MW
    Bioorg Med Chem Lett; 2012 Aug; 22(16):5185-9. PubMed ID: 22796180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Assessment of susceptibility of strictly anaerobic bacteria originated from different sources to fluoroquinolones and other antimicrobial drugs].
    Lachowicz D; Skopińska E; Pawłowska J; Kostkiewicz M; Obuch-Woszczatyński P; Wultańska D; Pituch H
    Med Dosw Mikrobiol; 2012; 64(2):115-22. PubMed ID: 23072056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modelling biphasic killing of fluoroquinolones: guiding optimal dosing regimen design.
    Bhagunde P; Singh R; Ledesma KR; Chang KT; Nikolaou M; Tam VH
    J Antimicrob Chemother; 2011 May; 66(5):1079-86. PubMed ID: 21393141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Geographic distribution of fluoroquinolone-resistant Escherichia coli strains in Asia.
    Uchida Y; Mochimaru T; Morokuma Y; Kiyosuke M; Fujise M; Eto F; Harada Y; Kadowaki M; Shimono N; Kang D
    Int J Antimicrob Agents; 2010 Apr; 35(4):387-91. PubMed ID: 20138480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.